Learn the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.
William R. Short, MD, MPH, AAHIVS
Format: Microsoft PowerPoint (.ppt)
File Size: 428 KB
Released: November 3, 2021
Acknowledgements
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
